{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:22:25Z","timestamp":1791516145555,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.urology.2005.12.014","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T14:04:08Z","timestamp":1149775448000},"page":"1216-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":276,"title":["Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials"],"prefix":"10.1016","volume":"67","author":[{"given":"Rui Fa","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.12.014_bib1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer","volume":"168","author":"Richard","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0021-9681(87)90190-1","article-title":"Guidelines for reading case control studies","volume":"40","author":"Lichtenstein","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.urology.2005.12.014_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Gu\u00e9rin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib4","first-page":"767","article-title":"Results of adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy for grade 3 superficial bladder cancer","volume":"50","author":"Yumura","year":"2004","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.urology.2005.12.014_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1464-410X.2004.04556.x","article-title":"T1G3 transitional cell carcinoma of the bladder","volume":"93","author":"Peyromaure","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2005.12.014_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib7","first-page":"187","article-title":"Immunoprophylactic intravesical application of bacillus Calmette-Gu\u00e9rin after transurethral resection of superficial bladder cancer","volume":"44","author":"Librenjak","year":"2003","journal-title":"Croat Med J"},{"key":"10.1016\/j.urology.2005.12.014_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","article-title":"Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Gu\u00e9rin for superficial bladder cancer recurrence","volume":"10","author":"Irie","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib9","first-page":"201","article-title":"Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study","volume":"83","author":"Tong","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.urology.2005.12.014_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1442-2042.2003.00559.x","article-title":"Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder","volume":"10","author":"Hara","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Gu\u00e9rin for primary stage T1 grade 3 bladder cancer","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin treatment improves patient survival in T1G3 bladder tumours","volume":"41","author":"Patard","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2005.12.014_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1464-410X.2002.02692.x","article-title":"Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Gu\u00e9rin therapy","volume":"89","author":"Kolodziej","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2005.12.014_bib16","first-page":"70","article-title":"Features of BCG-therapy in treating patients with superficial bladder cancer","volume":"74","author":"Chepurov","year":"2002","journal-title":"Ter Arkh"},{"key":"10.1016\/j.urology.2005.12.014_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","article-title":"Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Gu\u00e9rin therapy for carcinoma in situ of the bladder","volume":"8","author":"Sekine","year":"2001","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","article-title":"Intravesical instillation of epirubicin, bacillus Calmette-Gu\u00e9rin and bacillus Calmette-Gu\u00e9rin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000051005","article-title":"Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Gu\u00e9rin is not indicated for superficial bladder cancer","volume":"67","author":"Tozawa","year":"2001","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2005.12.014_bib20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1007199932271","article-title":"The best management of superficial bladder tumours","volume":"32","author":"Altay","year":"2000","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2005.12.014_bib22","first-page":"760","article-title":"The prevention of stage-T1 superficial bladder tumors with 27 mg. of BCG weekly over 6 weeks","volume":"52","author":"Moyano Calvo","year":"1999","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Gu\u00e9rin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Gu\u00e9rin versus mitomycin C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Gu\u00e9rin-RIVM and mitomycin C in superficial bladder cancer","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.12.014_bib26","first-page":"206","article-title":"Results of BCG in the treatment of pTa and pT1 bladder tumors","volume":"8","author":"Ayed","year":"1998","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","article-title":"Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1)","volume":"50","author":"Jimenez-Cruz","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.12.014_bib28","first-page":"585","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer","volume":"28","author":"Bohle","year":"2002","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urology.2005.12.014_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Gu\u00e9rin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505017681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505017681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:44:49Z","timestamp":1758764689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505017681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0090429505017681"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.12.014","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2005.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}